Details for New Drug Application (NDA): 016774
✉ Email this page to a colleague
NDA 016774 describes SERENTIL, which is a drug marketed by Novartis and is included in three NDAs. Additional details are available on the SERENTIL profile page.
The generic ingredient in SERENTIL is mesoridazine besylate. There are two drug master file entries for this compound. Additional details are available on the mesoridazine besylate profile page.
The generic ingredient in SERENTIL is mesoridazine besylate. There are two drug master file entries for this compound. Additional details are available on the mesoridazine besylate profile page.
Summary for 016774
| Tradename: | SERENTIL |
| Applicant: | Novartis |
| Ingredient: | mesoridazine besylate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 016774
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
